{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Afrezza+Dose+2",
    "query": {
      "intervention": "Afrezza Dose 2"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 541,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Afrezza+Dose+2&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T20:19:49.467Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00355849",
      "title": "Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Human Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 555,
      "start_date": "2006-08",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2019-09-16",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 24,
      "location_summary": "Fresno, California • Pomona, California • West Palm Beach, Florida + 21 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00355849"
    },
    {
      "nct_id": "NCT03713684",
      "title": "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Efpeglenatide SAR439977",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 370,
      "start_date": "2018-11-09",
      "completion_date": "2021-01-04",
      "has_results": true,
      "last_update_posted_date": "2021-12-02",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03713684"
    },
    {
      "nct_id": "NCT05514535",
      "title": "A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Insuline glargine U100 (reduced)",
          "type": "DRUG"
        },
        {
          "name": "Insuline glargine U100 (titrated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 573,
      "start_date": "2022-08-29",
      "completion_date": "2025-04-09",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 145,
      "location_summary": "Sheffield, Alabama • Glendale, Arizona • Mesa, Arizona + 113 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514535"
    },
    {
      "nct_id": "NCT01768559",
      "title": "Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine QD",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine TID",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine (Mandatory background drug)",
          "type": "DRUG"
        },
        {
          "name": "Metformin (Background drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 894,
      "start_date": "2013-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-04",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 46,
      "location_summary": "Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768559"
    },
    {
      "nct_id": "NCT06354088",
      "title": "Human Models of Selective Insulin Resistance: Alpelisib, Part I",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Prediabetic State",
        "Overweight and Obesity",
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Alpelisib 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "[1-13C] sodium acetate",
          "type": "DRUG"
        },
        {
          "name": "[6,6-2H2] D-glucose",
          "type": "DRUG"
        },
        {
          "name": "Mixed Meal Tolerance Test",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Nestlé BOOST Plus",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2024-04-24",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06354088"
    },
    {
      "nct_id": "NCT05184868",
      "title": "AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "AT247",
          "type": "DRUG"
        },
        {
          "name": "NovoLog",
          "type": "DRUG"
        },
        {
          "name": "Fiasp",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arecor Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2022-01-03",
      "completion_date": "2022-09-09",
      "has_results": false,
      "last_update_posted_date": "2022-09-13",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05184868"
    },
    {
      "nct_id": "NCT05790681",
      "title": "A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin icodec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 18,
      "start_date": "2023-04-25",
      "completion_date": "2024-02-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05790681"
    },
    {
      "nct_id": "NCT05541939",
      "title": "Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postbariatric Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Mizagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vogenx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2022-09-13",
      "completion_date": "2023-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Aurora, Colorado",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05541939"
    },
    {
      "nct_id": "NCT03170544",
      "title": "Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "MK-1092, 4.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 8.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 16 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 32 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 64 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Glargine 3.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Lispro 1.2 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to glargine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to MK-1092",
          "type": "DRUG"
        },
        {
          "name": "Dextrose",
          "type": "OTHER"
        },
        {
          "name": "Insulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-08-16",
      "completion_date": "2018-11-08",
      "has_results": true,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170544"
    },
    {
      "nct_id": "NCT04460326",
      "title": "Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Treated With Insulin"
      ],
      "interventions": [
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "NovoLog",
          "type": "DRUG"
        },
        {
          "name": "Insulin Fiasp",
          "type": "DRUG"
        },
        {
          "name": "Standard carbohydrate diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-12-07",
      "completion_date": "2023-05-27",
      "has_results": true,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-09-03T20:19:49.467Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04460326"
    }
  ]
}